Monte Rosa Therapeutics vs Invivyd
GLUE and IVVD side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How GLUE and IVVD compare
Monte Rosa Therapeutics is the larger company, worth 4.9 times as much as Invivyd ($781M against $158M).
Invivyd grew revenue faster over the last twelve months (26.3% versus −83.9% for Monte Rosa Therapeutics).
Invivyd keeps more of each dollar of sales as profit, with a net margin of −184% compared with −561% at Monte Rosa Therapeutics.
Invivyd scores higher on the StockData Score (9 against 7 for Monte Rosa Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | GLUE | IVVD |
|---|---|---|
| Size and price | ||
| Market cap | $781M | $158M |
| Share price | $9.16 | $0.538 |
| Change, 1 year | −36.0% | −69.6% |
| Change, 5 years | −55.4% | −97.9% |
| Beta (5Y) | 2.01 | 2.47 |
| Employees | 150 | 122 |
| StockData Score | ||
| Total score | 7 | 9 (better) |
| Valuation score | 1 | 3 (better) |
| Growth score | 0 | 1 (better) |
| Performance score | 1 (better) | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 27.2× | 2.7× (better) |
| P/B | 1.6× | 0.9× (better) |
| FCF yield | −4.1% (better) | −69.2% |
| Fair value | $6.49 | $0.983 |
| Margin of safety | −41.2% | 45.3% (better) |
| Growth | ||
| Revenue growth (TTM) | −83.9% | 26.3% (better) |
| Net income growth (TTM) | −767% | – |
| EPS growth (TTM) | −707% | – |
| Profitability | ||
| Operating margin | −633% | −193% (better) |
| Net margin | −561% | −184% (better) |
| FCF margin | −112% (better) | −188% |
| Return on equity | −42.7% (better) | −95.9% |
| Return on invested capital | – | −616% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 10.58 (better) | 5.87 |
| Altman Z-score | 1.32 (better) | −4.74 |
| Piotroski F-score | 5 | 5 |
| Dividends and buybacks | ||
| Buyback yield | – | −0.24% |
| Shareholder yield | 0.00% (better) | −0.24% |
| Ownership | ||
| Held by institutions | 109% | 79.0% |
| Held by insiders | 11.5% | 16.7% |
| Insider net buying, 12 months | −$4.1M | −$531K (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 27.6% | 14.7% |
Go deeper
- GLUE stock overview
- GLUE income statement
- GLUE valuation and score
- IVVD stock overview
- IVVD income statement
- IVVD valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.